Trial Parameters
Brief Summary
The study objective is to improve accuracy in the early detection of neurodevelopmental impairment, especially CP, by evaluating the timepoint (in weeks post term age) that the Prechtl GMA is most useful for prediction of neurodevelopmental impairment at two years of age in children with and without medical complexity. The study team plans to recruit 100 healthy, term-born infants and 250 infants at risk of developing CP for a total of 350 enrolled infants.
Eligibility Criteria
Inclusion Criteria: * Infants born full-term with typical development, bithweight \>2500g * Infants with a history of brochopulmonary dysplasia, defined as having a preterm birth (\<33 weeks gestational age) and requiring supplemental oxygen beyond 36 weeks gestational age * Infants with neonatal encephalopathy, who required hypothermic cooling treatment * Infants born \<36 weeks gestational age * Infants born in a multiple gestation pregnancy * Infants with a diagnosis of Trisomy 21 * Infants born and diagnosed with SMA prenatally, via newborn screening assessment or prior to 10 weeks corrected age * Infants are less than 10 weeks corrected age at time of enrollment Exclusion Criteria: * Children who are enrolled in DCFS custody * Parent or infant guardian does not have a smartphone